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Abstract
Gaucher disease (GD) is a rare inherited metabolic disorder and the 
most common lysosomal storage disorder, caused by a deficiency in 
glucocerebrosidase enzyme activity. It has been classified according 
to the neurological manifestations into three types: type 1, without 
neuropathic findings, type 2 with acute infantile neuropathic signs 
and type 3 or chronic neuropathic form. However, report of new 
variants has led to the expansion of phenotype as a clinical phenotype 
of GD considered as a continuum of phenotypes. Therefore, it seems 
that a new classification is needed to cover new forms of the disease.
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Introduction
Lysosomal storage disorders (LSDs) are a different group of 
nearly sixty inherited metabolic diseases (1) characterized by 
an accumulation of harmful products in the lysosomes because 
of malfunction of its specific proteins. As a result of a lysosomal 
dysfunction, cellular function disrupts and clinical abnormalities 
appear subsequently. In respect of the intracellular depository 
material, LSDs can be divided into three major groups including the 
sphingolipidoses, mucopolysaccharidoses, and glycoproteinoses (2). 
Gaucher disease (GD, OMIM #230800, ORPHA355) is the most 
common sphingolipidoses (1, 3) with an accumulation of the toxic 
amounts of certain fatty materials- glucosylceramide- primarily 
within the lysosomes of macrophages in the diverse tissues, 
transforming macrophages into storage cells named Gaucher cells 
throughout the body (4, 5). 
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History
GD was first recognized by a French doctor in 
1882 (6). He described a young female patient with 
a huge splenomegaly without evidence of malignancy 
rather the presence of largely unusual cells in the 
involved spleen. After reporting other similar patients, 
the autonym “Gaucher’s disease” was denoted (7). 
Neurologic impairment in an infant was first reported 
in 1927(8). This phenotype eventually became known 
as the infantile or acute neuronopathic form (9). In 
the 1960s, the pathogenesis of GD was described: A 
functional deficiency of β-glucocerebrosidase activity 
as the primary pathomechanism (10). 
Classification
GD is classically divided into two major clinical 
subgroups and three main subtypes (Figure 1) 
according to the absence or presence of neurological 
involvement with its severity and deterioration, age 
at determination and progression rate (11-13). 
1) Non-neuronopathic group
This group includes Type 1 GD (OMIM #230800; 
ORPHA: 77259)’ also known as adult and chronic 
GD (14, 15) which is the most prevalent subtype in 
the Western countries (12, 16, 17). It is characterized 
by the visceral presentations without CNS involvement 
(18) distinguishing from the other two types in 
neuropathic group (19). 
2- Neuronopathic group
Two types of GD are described under this group 
originally as follows:
Type 2 (OMIM #230900; ORPHA: 77260) is 
known as acute neuronopathic or infantile GD (14, 
15), manifests early at infancy (17). It is also the 
most severe form of GD characterized by CNS 
involvement (1). Rapid progression with severe 
deterioration course, leads to death in infancy or 
early childhood usually before the age of 2 year 
(17, 20, 21). 
Type 3 (OMIM #2301000; ORPHA:77261) is 
known as chronic neuronopathic or juvenile GD 
or subacute neuronopathic GD (14, 15). It is 
characterized by less severe CNS involvement (1) 
and can be confused therefore, with type 1 GD in 
its early stages (19). It includes several different 
phenotypes (22) in childhood, adolescence or 
early adulthood (23-25), and further is divided into 
subgroups: 3a, 3b, and 3c (26-28). 
New insights to neuropathic variants
In fact, because any combination of the GD’s types 
may occur in any individual patient, it is increasingly 
recognized that this classification is somewhat non 
practical (22). Recognition of a subset of patients 
with type I GD who developed PD (29) and 
peripheral neuropathies (30), has led to the expansion 
of phenotype as a clinical phenotype of GD to be 
considered as a continuum of phenotypes (31). 
Therefore, it appears that classification of GD 
needs to be modified periodically as the new variants 
introduced. Accordingly, we revised current 
conventional classification to the new expanded 
classification based on literature (9, 15-17, 27, 30-
40) (Figure 1). 
Epidemiology
Nowadays, GD is classified in “orphan diseases” 
category, which comprises a group of rare 
disorders with prevalence of 1:50,000 or lower in 
the general population (1). The incidence of GD 
is 1 in 40,000 - 60,000 to 100,000 births in the 
general population but it could reach up to 1 in 800 
- 1,000 in Ashkenazi Jewish populations (5, 41). 
GD affects men and women equally. According 
to a report by the National Organization for Rare 
Disorders, the GD incidence rate may be as high as 
1 in 450 births among individuals with Ashkenazi 
Jewish ancestry and 1:20 000 to 1:200 000 in the 
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Figure 1: New expanded classification of GD
general population (42-44). The other forms of GD 
are uncommon and do not occur more frequently 
in people of Ashkenazi Jewish descent (45).  
GD1: Type 1 is the most common form of the 
disorder with a prevalence of 1 in 50,000 to 100,000 
(19) accounting for 95% of all GD cases (26). It 
occurs more frequently in people of Ashkenazi 
(Eastern and central European) Jewish heritage 
than in those with other backgrounds. This form 
of the condition affects 1 in 500 to 1,000 people of 
Ashkenazi Jewish heritage (45).
GD2: Type 2 GD makes up the minority of GD 
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cases overall. In general, GD has an estimated 
frequency of 1 in 100,000 to 500,000 live births 
(46, 47). Like other types of GD, type 2 GD is pan-
ethnic in occurrence (33). 
GD3: Type 3 GD is also a rare form that affects 
fewer than 1 in 100 000 people (26-28). 
Genetic and inheritance pattern
GD is inherited in an autosomal recessive pattern 
which means both parents must be heterozygote 
carriers of a mutated gene for production of an 
affected zygote during conception. 
In each pregnancy, the chance of fetus to have two 
(i. e., affected) or no (i. e., unaffected) mutated 
genes is 25%. Moreover, there is a 50% chance 
with each pregnancy that the offspring have a 
mutation from one of parents (i. e., heterozygote 
carrier). Heterozygote carriers typically do not 
reveal clinical features of the condition (46-49). 
GD is caused by the mutations in the glucocerebrosidase 
(GBA) gene on the first chromosome (1q21), 
composing of 11 exons and 10 introns with 7. 6 kb 
in length (23). Mutations in the GBA gene cause all 
three primary forms of GD by altering the stability 
of the glucosylceramidase or its active site. To date, 
more than 300 mutations have been described (50). 
Pathophysiology and Neuropathogenesis
Glycosphingolipids (GSLs) are essential components 
of eukaryotic cell membranes synthesized in the 
endoplasmic reticulum and Golgi apparatus and 
degraded in the lysosomes. They are vital for life 
(7, 51). 
Glucocerebrosidase also called glucosylceramidase 
(GlcCerase, GCase) or acid beta-glucosidase is the 
lysosomal hydrolase coded by the GBA gene (3-5). 
Glucocerebroside also known glucosylceramide 
(GlcCer) is the simplest GSL in the cell membrane 
of many organs that normally hydrolyzed into 
glucose and a simpler fat molecule called ceramide 
by GlcCerase (8, 10). 
Any mutation in the GBA1 gene causes a diminished 
activity of GCase. Its deficiency, consequently lead 
to the accumulation of GlcCer in the lysosomes 
of macrophages, transforming them into storage 
cells called Gaucher cells (Figure 2) and cellular 
dysfunction (52). The exact pathophysiological 
mechanisms of neurotoxicity are not understood (3) 
and it is probably different than those of systemic 
involvement (53). Gaucher cells are found in the 
brain of patients with neuronopathic GD associated 
with neuronal loss and glial activation (54, 55). 
Because the GlcCer turnover in neurons is low, its 
accumulation is considered significant only when 
residual GCase activity is notably diminished (56). 
In the neuronopathic GD, Gaucher cells can 
be found in the perivascular regions and brain 
parenchyma. In the areas with neuronal loss of 
the type II GD, brain parenchyma involvement 
especially in cortical layers III and V, hippocampus 
brainstem and cerebellum is more frequently 
reported (54-56). 
Clinical features
GD may occur at any age, ever fetus and in any 
humanity as well as geographical districts (16). It 
is a progressive disorder with a broad spectrum 
of non-neurological and neurological clinical 
findings and their variable severity, ranging from 
neonatal lethal form to asymptomatic subset (16, 
20). Variation in the clinical manifestation can 
be explained by continuum of phenotype (4). All 
types of GD usually have some degree of visceral 
involvement with the potential for overlapping 
manifestations (24). According to the ICGG 
Gaucher Registry data, the frequency of clinical 
features for all types of GD include the following 
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as a descending order: Splenomegaly (85%), 
thrombocytopenia with or without bleeding (68%), 
hepatomegaly (63%), osteopenia (55%), failure to 
thrive ( 36%), anemia (34%), bone pain( 33% ), 
fractures (7%) and bone crises (7%)(16). Pulmonary 
involvement is rare in all GD phenotypes and seems 
more frequent in patients homozygous for the 
1448G (L444P) mutation (3). 
As mentioned in classification section, conventional 
and universally-accepted variants of GD include 
non-neuropathic (type 1 GD) form and neuropathic 
(type 2 GD and type 3 GD) forms (14-18). 
I) Non neuropathic GD
• Type 1 GD 
Traditionally, lack of nervous system involvement 
is necessary for a diagnosis of type I GD. However, 
despite of the customary definition of type 1 GD, 
some neurological features are reported with 
this phenotype. Therefore, presence of non-
neurological features as exclusively diagnostic 
criteria of type I GD was questioned (57-67). 
The recognition of new atypical phenotypes with 
intermediate features and considering that even 
patients with type 1 GD can be present with some 
late-onset neurological presentations, has led to 
Figure 2: Pathogenesis cascade of GD
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the concept that GD is a continuum of phenotypes 
(Figure 3) (4-7,39,52). 
1) Neurological manifestations
 In Type 1 GD, the nervous system may be 
affected secondarily as a consequence of vertebral 
involvement resulting from severe hematological 
and skeletal problems (17, 57). Either vertebral 
collapse or extraosseous accumulation of Gaucher 
cells may cause spinal cord compression and/or 
nerve root compression (17) resulting in secondary 
neurological complications such as upper motor 
neuron presentations (57). 
Although there are no primary neurological 
manifestations in type1GD, certain neurological 
presentations such as PD and peripheral neuropathy 
in association with this type have been reported in 
recent years (3, 17). The frequency of PD (58-60) 
and symptomatic peripheral neuropathies (61) in 
type 1GD is higher than in the general population 
(57). The risk of developing PD in type 1 GD is 
5%-7% and 9%-12% before the age 70 and 80 
years, respectively (62). The life-time risk of 
developing PD is an approximately 26-fold higher 
than the general population (62, 63), often at an 
earlier age (mean approximately 4–5 yr earlier) 
(59-61). Moreover, the risk of developing PD may 
Figure 3: Phenotypic continuum of GD
GD GD GD
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be increased in the heterozygote carrier state. The 
patients can present with typical features including 
an asymmetric onset of rigidity, resting tremor, and 
bradykinesia that is responsive to levodopa (64). 
It is not evident whether peripheral neuropathy 
is related to GD, medications or just coincidence 
(17). Besides, the patients can exhibit atypical and 
non-motor features such as anxiety, supranuclear 
oculomotor signs, cognitive impairments, 
dementia, sleep (REM) disorders, hallucinations 
and apraxia (58, 64-66). 
2) Non neurological manifestations
 The clinical presentation is variable; it can 
be either asymptomatic throughout the life or 
symptomatic in childhood (2-6). The patients can 
be present with any symptoms and diagnosed at 
any age (41). According to the literature, common 
non neurological clinical features of type 1 GD 
and their frequency include splenomegaly (90%) 
(67, 68); thrombocytopenia (60-90%) (69); bone 
marrow infiltration (80%)(70); hepatomegaly (60-
80%)(41); fatigue (50%) (71); anemia (20-50%) 
(72); growth retardation (34%) (71); gallstones 
(32%) (73); acute painful bone crises (30%) (72); 
and avascular necrosis (15%) (74). 
Moreover, there are some uncommon features such 
as renal involvement, skin involvement, ocular 
manifestations and vitreo-retinal involvement, 
myocardial or valvular involvement, insulin 
resistance and amyloidosis (3). 
II) Neuropathic GD
Neuronopathic GD types are rare and constitute 
about 6% of GD (5% for type 3 GD and 1% for type 
2 GD) (35). A definite diagnosis neuronopathic GD 
(NGD) is best established if there are neurological 
symptoms and signs in biochemically proven 
disease while other etiologies have been ruled out 
(22,75). Neurologic symptoms are characteristic 
hallmark for types 2 and 3 GD (27). As mentioned 
in classification section, two types of GD are 
described under this group. 
Conventional types
• Type 2 GD 
Type 2 GD, generally, occurs in infancy with 
severe systematic presentations specially 
hepatosplenomegaly and neurological features 
manifesting with a rapidly progressive course (33). 
Non perinatal-lethal (Classical or infantile) subtype
1) Neurological manifestations
 Neurological features may manifest before 
splenomegaly or concurrently (52). All patients 
with type 2 GD experience a rapid neurological 
deterioration (12). 
The prevalent neurological presentations can be 
originated from three main anatomical regions 
including brainstem, pyramidal tracts (corticobulbar 
and corticospinal tracts) and extrapyramidal tracts 
(12, 22, 23, 39, 52, 76). Neurodegenerative disease 
usually appears in six months and progress to a 
classic picture of disease characterized by triad 
of “, swallowing and sucking problems, acquired 
strabismus caused by bilateral 6th nerve palsy and 
hyperextension of the neck and trunk” (22, 23, 52). 
The later eventually progresses to opisthotonus, 
probably due to meningeal irritation (39, 52). Aside 
strabismus, other oculomotor abnormalities include 
impaired vision, oculomotor apraxia, Saccadic 
initiation failure, opticokinetic nystagmus, absence 
of visual fixation and ophthalmoparesis (76). 
Manifestations of brainstem involvement appear in 
early infancy before other neurological symptoms 
and signs (23, 52, 77). The brainstem deterioration 
proceeds progressively and after a few months the 
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infant ultimately present with either stridor leading 
to laryngeal obstruction and apnea, or to dysphagia 
precipitating aspiration (23, 78). Laryngeal stridor 
is the consequence of bulbar palsy (79-82). 
Adduction and flexion posturing of the thumb, 
also referred to as “cortical thumb” sign is normal 
finding in term newborns (79). However, persistent 
cortical thumb sign beyond 4 months of age 
considered pathological finding (80). It may be a 
sign of one of pyramidal tracts involvement, as in 
type 2 GD (12, 22, 81). Retroflexion of the neck, 
probably due to laryngomalacia and hypotonia of 
pharyngeal muscles (12, 22, 52) as well as motor 
dysfunction including hypertonia, hyperreflexia 
and expressionless facies or athetosis (23, 33, 39, 
52) are other signs of pyramidal tracts involvement. 
However, children are at first hypotonic and then 
hypertonic (52, 76). Extrapyramidal rigidity may 
be seen as well (12, 22). 
Psychomotor development may be delayed initially 
or regressed after a period of normal development. 
Some patients, however, continue to acquire 
new skills despite disease progression (12, 52). 
Other neurological features include universally 
impaired cognition, progressive microcephaly, 
arthrogryposis, myoclonic jerks, deafness and 
epilepsy (12, 39, 76). Seizures occurring later 
manifest as myoclonic epilepsy that is refractory 
to antiseizure medications (23, 83, 84). The 
EEG feature include polyspike discharges seen 
occipital region predominantly are sensitive to 
photostimulation; multifocal spike-and-wave 
paroxysms; and diffuse slowing with high-voltage 
sharp wave activity during sleep (85). Abnormal 
brain stem auditory evoked response (BAER) 
testing, abnormal visual evoked potentials (VEP) 
and mild cortical atrophy on brain MRI have been 
reported(76, 83). 
2) Non neurological manifestations
 Affected newborns often appear normal at birth, 
but the disease manifests by 3 to 6 months (39, 84). 
Failure to thrive (30% of cases) may be the first 
sign makes parents to seek medical attention. It can 
progress to cachexia in the presence of insufficient 
nutritional intake (39). Splenomegaly (59% of 
cases) almost always is the most common finding 
detected in the onset of disease. Hypersplenism 
is associated with thrombocytopenia in 60% of 
cases with or without anemia and leukopenia, 
usually followed by hepatomegaly (39, 52). 
Bone involvement is not seen in the type 2 GD, 
perhaps because there is no sufficient time for the 
skeletal system involvement (82). Interstitial lung 
disease occurs due to chronic aspiration, repeated 
respiratory infections and Gaucher cell infiltration 
(12, 22, 39, 52). Repeated aspiration and/or 
prolonged and frequent apnea are the cause of 50% 
of deaths (23). 
Perinatal-lethal (Fetal-Neonatal) subtype
The prevalence of this type is lower than one 
percent (86). It is the most severe form of GD (37). 
The activity of residual GBA is almost zero (87). 
The patients can present with either non-immune 
hydrops fetalis or neonatal ichthyosiform-collodion 
cutaneous abnormalities (85). 
Perinatal-lethal GD with triad of “hydrops, 
ichthyosis, and fetal akinesia sequence” has been 
associated with specific severe mutations (87). 
1) Neurological manifestations
Neurological features include signs overlapping 
with classical type 2 GD including bulbar and 
pyramidal presentations (12, 22, 23, 39, 52, 76, 
81), hypokinesia (43%) with facial dysmorphia 
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(35%) such as low-set ears, a small nose with a 
flat nasal bridge and anteverted nares) (33), and 
arthrogryposis plus contractures of distal joints 
(club foot, camptodactyly) (30%) (23, 88, 89, 90). 
2) Non neurological manifestations
 Non-neurological feature include prematurity, 
non-immune hydrops fetalis (22, 88), fetal demise 
or death usually within the first few days of life 
(22, 87, 89), hepatosplenomegaly (92%) (23), 
thrombocytopenia (38%) associated with purpura 
(22%), anemia (10%), bone marrow involvement 
with Gaucher cells (88), and neonatal lamellar 
ichthyosis (collodion baby) phenotype (41%), 
where infants appear to be covered by a cellophane 
membrane at birth (12, 88) exhibiting erythematous 
and shiny skin predominately over the palms 
and soles or in flexural folds (33). Death occurs 
secondary to non-neurological
complications including lung hypoplasia caused 
by plural effusion, hepatic failure, and
gastrointestinal tract bleeding (12, 22, 23, 33, 88, 
90). 
• Type 3 GD 
Type 3 GD is more prevalent than type 2 GD 
(5% versus 1%) due to longer survival in affected 
patients (52, 91). It is generally associated with 
later onset in childhood compared with type 2 GD 
(91), although the patients may present between 
infancy and adolescence, mostly in the first 5 years 
of life particularly before the age of two years 
(52, 82, 92). Therefore, the life span may extend 
as far as the 5th or even the 6th decade (93, 94). 
However, they will seek a medical advice during 
childhood, adolescence, and even adulthood if the 
non-neurological symptoms are not evident (12, 
22), representing variable nature of the patients’ 
history as well as a phenotypic continuum of type 3 
GD (12, 22, 52). 
The clinical expression of type 3 GD can be complex 
as a combination of visceral presentations of type 
1 GD with neurological features of type 2 GD (52, 
82). This feature may be challenging as it can lead 
to difficulty in distinguishing between type 2 GD 
and type 3 GD, and infrequently even between 
type 3 GD and type 1 GD (95, 96). It is generally 
characterized by visceral and less severe CNS 
involvement (1, 7, 23, 24). The patients may present 
in childhood with some degree of neurological 
manifestations as well as hepatosplenomegaly, 
hematological presentations such as anemia and 
thrombocytopenia, and osteopathy features such 
as bone crises and kyphosis (97). Death occurs 
in patients with severe progressive neurological 
deterioration, mainly caused by late involvement 
of the brainstem and related complications such 
as swallowing problems followed by recurrent 
aspiration and respiratory compromise (52). 
1) Neurological manifestations
 Type 3 GD shows a slower neurological 
involvement than type 2 GD (93). The neurological 
manifestations are a wide spectrum, ranging 
from mild oculomotor dysfunction to severe and 
rapidly progressive brain degeneration (52). In the 
International
Collaborative Gaucher Group (ICGG) Registry 
Study, half of the patients exhibited neurological 
presentations before two years of old (95). 
However, in the absence of N370S mutation, 
neurological features may be evident several years 
after occurrence of visceral presentations (98). 
Neurological presentations are a hallmark of type 
3 GD (97). 
1-1) Neuro-ophthalmic disorders
 The earliest and most common findings are 
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oculomotor anomalies (about 66% of patients) 
(52), characterized by a slowing, looping, or 
failure of the horizontal saccades movements 
(97, 99). Therefore, ophthalmologists are often 
primary physicians that visit the patients and then 
suggest diagnosis of type 3 GD (100). The slowed 
horizontal saccadic eye movements occasionally 
are the only neurological symptom (12). Clinically 
detection of the saccade initiation failure may be 
difficult. However, it can be simply exposed as 
absent quick phases by inducing optokinetic and 
vestibular nystagmus (101). Besides, involvement 
of vertical saccades may occur (52). 
1-2) Epileptic disorders
 The accurate estimation of epilepsy is not known, 
although it has been reported in 16% of patients in 
ICGG Registry Study (95). Different seizure types 
such as generalized and tonic-clonic types have 
been delineated but myoclonus and progressive 
myoclonic epilepsy reported more than other cases 
(95-102). 
Similar to type 2 GD (76, 83, 85), abnormal 
patterns can be seen in EEG including generalized 
background slowing or epileptiform discharges 
as the spike discharges (97, 102). Some patients 
may present with myoclonic epilepsy without 
clinically significant visceral storage. Therefore, it 
can be concluded that GCase deficiency screening 
should be considered in patients with progressive 
myoclonic epilepsy in setting of unknown 
underlying etiology (52). 
1-3) Cognition and intelligence disorders
 Cognitive deficits have been reported in 33% of 
the patients (52). Cognitive impairments typically 
affect general nonverbal skills with relative 
sparing of verbal skills (12). As a result, the 
verbal IQ is typically more than the performance 
IQ, suggesting a visual-spatial deficits possibly 
secondary to oculomotor or other motor problems 
(103). Some patients present with IQ lower 
than average along with language difficulties, 
perceptual organization skills, and several learning 
and functional disabilities (12, 97). Interestingly, 
patients can occasionally exhibit upper limit 
normal of IQ scale’s ranges, especially high verbal 
IQ scores with success in the college and higher 
degrees (12, 97, 103). 
1-4) Miscellaneous disorders
 Behavioral changes, dementia and unexpected death 
are described in some patients (23). Developmental 
delay, hearing impairment and other brainstem 
deficits have been reported. Abnormal “brainstem 
auditory and somatosensory” evoked potentials 
have also been noted in some individuals (95). 
Progressive kyphosis that may develop requiring 
spinal surgery (23). In the course of disease, 
progressive cerebellar ataxia or spasticity occur in 
about 20%–50% of patients affecting walking, and 
then standing (101). 
2) Non neurological manifestations
 Similar to type 2 GD, patients with type 3 GD 
can present with very aggressive visceral disease 
(104). Therefore, presentation with this phenotype 
at younger than 2 years of old is frequently 
associated with type 3 GD (22). Bone involvement 
is common; severe osteopenia and osteonecrosis 
of major joints, including the humeral and femoral 
heads can be a principle cause of morbidity (105). 
Pulmonary involvement have been reported at least 
50% of patients (92). Symptomatic patients usually 
present with shortness of breath on exercise, 
coughing, and wheezing. Pulmonary function 
tests show abnormalities of diffusion, occasionally 
with a restrictive pattern (22). Other features 
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include hepatomegaly, splenomegaly, anemia 
and thrombocytopenia, bony pain crisis, bony 
lytic lesions, bony infarctions, and pathological 
fractures (106). 
Subtype 3a GD
Subtype 3a GD is characterized by mild visceral 
involvement, but with severe rapidly progressive 
neurological manifestations including oculomotor 
apraxia, cerebellar ataxia, spasticity, progressive 
myoclonic epilepsy refractory to treatment, and 
dementia (12, 106). 
The prognosis is poor leading to death within the 
first two decades (13,102). The age of presentation 
as well as the rate of disease progression are 
variable (12). 
Subtype 3b GD
Unlike the subtype 3a GD, subtype 3b GD is 
characterized by massive visceral disease and 
skeletal manifestations but mild, slowly progressive 
CNS involvement (5, 27, 76, 106). Visceral 
features include massive hepatosplenomegaly, 
growth retardation as well as bony symptoms (13, 
35, 107). The horizontal supranuclear gaze palsy is 
the major neurologic sign (27, 35). 
Subtype 3c GD
Subtype 3c GD is an atypical rare variant (82) 
characterized by fatally progressive cardiac valves 
(tricuspid, mitral or aortic) and ascending aortic 
calcifications or fibrosis, supranuclear gaze palsy, 
mild hepatosplenomegaly, corneal opacities and 
bone disease and hydrocephalus and skeletal 
anomalies (5, 12, 13, 27, 52). This phenotype was 
first reported among Arab patients with GD from 
the Jenin area, but reported among other ethnic 
groups later (82). It is also exclusively associated 
with a complete genotype-phenotype correlation 
across several ethnicities with homozygosity 
for the D409H (G1342C) mutation (12, 22, 76). 
Although subtype 3c presents with a unique 
phenotype, considerable clinical overlap exists 
between subtypes 3a and 3b (35). They often die in 
early adulthood (13). 
Norrbottnian variant
The subtype 3 Norrbottnian GD is characterized 
by early onset massive visceral involvement, 
progressive kyphoscoliosis and mild cognitive 
deficits (76). Historically, this subtype may have 
arisen during or before the sixteenth century in 
northern Sweden (22). This form of GD affects 
approximately 40% of all known cases in Sweden 
(12). It is attributed to a founder effect for the 
L444P mutation (107). The founder effect is the 
phenomenon in which the high frequency of a 
specific gene defect within a defined population 
is explained by common ancestry (i. e., a shared 
identity by descent) (82). In the classic form 
of disease, the early clinical characteristics can 
lead to a diagnosis of type 1 GD (102). The first 
clinical symptoms occur at the median age of 1 
year (12). Visceral involvement characterized by 
the early onset of prominent hepatosplenomegaly, 
often requiring splenectomy at an early age (32). 
Moreover, patients can display hematological 
symptoms as well as skeletal involvement, often 
including a gibbous deformity and retinal infiltrates 
(12). Neurological manifestations include 
horizontal supranuclear gaze palsy, strabismus due 
to cranial nerve 6 palsy, ataxia, mild spasticity in 
the legs, epilepsy as myoclonic or complex partial 
seizure types, and a slowly progressive cognitive 
deterioration leading to dementia (108). 
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Non-conventional types
Saposin C deficiency
Saposins are the essential cofactors in multiple 
stages of the lysosomal degradation of 
sphingolipids which include a family of four 
small glycoproteins, known as saposin A, B, C 
and D (109, 110).These homologous proteins 
derived from sequential proteolysis of a common 
precursor protein, prosaposin (PSAP), encoded by 
the PSAP gene on chromosome 10 (111). Saposin 
C is an established activator for the hydrolytic 
activity of GCase. It is also plays a protective role 
in proteolytic degradation of GCase (112). As 
a result, mutation in saposin c domain of PSAP 
results in saposin c deficiency (111), a very rare 
cause of GD with normal GCase activity (52).The 
patients with saposin c deficiency almost always 
present with clinical presentations similar to those 
in type 3 GD (108-113).
Type 2-3 intermediate GD
This non-conventional neuropathic type 
encompasses patients who survive beyond 2 years 
of old. They present with intermediary phenotype 
including clinical features between type 2 and 
type 3 GD (33). Similar to type 2 GD, the non- 
neurological presentations are mild to moderate 
(in contrast to type 3 GD).On the other hand, like 
to type 3 GD, typical neurological manifestations 
such as refractory myoclonic epilepsy are frequent 
which is in contrast to typical neurological features 
of type 2 GD(33, 52).It seems that several factors 
such as genetic modifiers, epigenetics, and 
probably environmental factors play a role not only 
to intermediate phenotype but also to other atypical 
GD phenotypes, like type 1 GD association with 
parkinsonism and peripheral neuropathy discussed 
earlier (114, 115).
In Conclusion, unlike previous studies that 
categorized different types of GD by existence of 
neurological involvements, based on recent studies, 
we convinced, there is a continuum range of 
symptoms in different types and subtypes of GD as 
type 1 can also be presented by some neurological 
disorders. Therefore, the neurological symptoms 
are not the definite criteria for differentiation 
between different types of gauche disease, and 
genetic testing is required for confirmation of 
diagnosis and determining a treatment plan. 
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